DeepMed Research

Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)

Phase 2

Recruiting

Conditions: Soft Tissue Sarcomas
Angiosarcoma
Fibrosarcoma
Leiomyosarcoma
Pleomorphic Liposarcoma
Malignant Peripheral Nerve Sheath Tumor (MPNST)
Desmoplastic Small Round Cell Tumor

Interventions: Drug: Tislelizumab+liposomal doxorubicin+ifosfamide

First Posted Date: 2025-03-25

Last Posted Date: 2025-04-03

Lead Sponsor: Fudan University

Target Recruit Count: 45

Registration Number: NCT06849986

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

HAIC Combined with Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)

Phase 2

Recruiting

Conditions: Hepatocellular Carcinoma (HCC)

Interventions: Drug: Sintilimab
Drug: Bevacizumab Biosimilar
Procedure: HAIC

First Posted Date: 2025-03-25

Last Posted Date: 2025-03-26

Lead Sponsor: Fudan University

Target Recruit Count: 164

Registration Number: NCT06860490

Locations: 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

The Efficacy and Safety of Narlumosbart in Combination with Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined with Immunotherapy in Patients with Bone Metastases from Advanced Non-small Cell Lung Cancer

Phase 2

Not yet recruiting

Conditions: NSCLC
Stereotactic Body Radiation Therapy (SBRT)
Immunotherapy

Interventions: Drug: Narlumosbart

First Posted Date: 2025-03-25

Last Posted Date: 2025-03-27

Lead Sponsor: Fudan University

Target Recruit Count: 27

Registration Number: NCT06738160

A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.

Not Applicable

Not yet recruiting

Conditions: Triple Negative Breast Cancer Metastatic
Melanoma Metastatic

First Posted Date: 2025-03-21

Last Posted Date: 2025-03-21

Lead Sponsor: Fudan University

Target Recruit Count: 66

Registration Number: NCT06889610

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

MRD-Guided Surveillance in Operable Colon Adenocarcinoma (I-III)(SURVEILLANCE-I)

Not yet recruiting

Conditions: Colorectal Cancer (CRC)

First Posted Date: 2025-03-17

Last Posted Date: 2025-03-17

Lead Sponsor: Fudan University

Target Recruit Count: 390

Registration Number: NCT06879873

MRD-Guided Surveillance in Resectable Stage IV Metastatic Colorectal Cancer (SURVEILLANCE-II)

Not yet recruiting

Conditions: Colorectal Cancer (CRC)
Colorectal Cancer Liver Metastases (CRLM)

First Posted Date: 2025-03-17

Last Posted Date: 2025-03-17

Lead Sponsor: Fudan University

Target Recruit Count: 181

Registration Number: NCT06879886

MRD-Guided Surveillance in Locally Advanced Mid-Low Rectal Cancer (SURVEILLANCE-III)

Not yet recruiting

Conditions: Colorectal Cancer (CRC)

First Posted Date: 2025-03-17

Last Posted Date: 2025-03-17

Lead Sponsor: Fudan University

Target Recruit Count: 139

Registration Number: NCT06879899

Cryoablation Combined With Lenvatinib Plus Tislelizumab Compared With FOLFOX in Patients With Advanced Intrahepatic Cholangiocarcinoma (CASTLE-ZS-01)

Phase 2

Recruiting

Conditions: Intrahepatic Cholangiocellular Carcinoma

Interventions: Drug: Tislelizumab
Drug: FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
Drug: Lenvatinib
Procedure: cryoablation

First Posted Date: 2025-03-06

Last Posted Date: 2025-04-06

Lead Sponsor: Fudan University

Target Recruit Count: 92

Registration Number: NCT06860477

Locations: 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined with Local Treatment in Advanced Colorectal Cancer

Phase 2

Recruiting

Conditions: Metastatic Colorectal Cancer (CRC)

Interventions: Drug: TAS-102+bevacizumab+local treatment
Drug: Standard chemotherapy

First Posted Date: 2025-03-04

Last Posted Date: 2025-03-04

Lead Sponsor: Fudan University

Target Recruit Count: 119

Registration Number: NCT06856187

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer

Not Applicable

Recruiting

Conditions: Advanced HR - Positive, HER2 - Negative Breast Cancer
Resistant to (Neo)Adjuvant Endocrine Therapy

Interventions: Drug: Sirolimus (albumin - bound)
Drug: Palbociclib
Drug: Fulvestrant

First Posted Date: 2025-03-04

Last Posted Date: 2025-03-04

Lead Sponsor: Fudan University

Target Recruit Count: 36

Registration Number: NCT06856200

Locations: 🇨🇳
Cancer Hospital Affiliated to Fudan University, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy